{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:07Z","timestamp":1793298907899,"version":"4.5.0"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2\u20133% of the world\u2019s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity. The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy. This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16). The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; p = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; p = 0.002)). The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (p &lt; 0.05). A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified, as well as a significant decrease in the level of low-density cholesterol (LDL) (p &lt; 0.05). In conclusion, semaglutide, based on its systemic anti-inflammatory characteristics, could contribute to the treatment of psoriatic obese patients with T2DM.<\/jats:p>","DOI":"10.3390\/biom15010046","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T11:24:19Z","timestamp":1735730659000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial"],"prefix":"10.3390","volume":"15","author":[{"given":"Jelena","family":"Petkovi\u0107-Dabi\u0107","sequence":"first","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Clinic of Skin and Venereal Diseases, University Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Bini\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana","family":"Cari\u0107","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-2391","authenticated-orcid":false,"given":"Ljiljana","family":"Bo\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5460-8568","authenticated-orcid":false,"given":"Sanja","family":"Umi\u010devi\u0107-\u0160ipka","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Clinic of Skin and Venereal Diseases, University Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Bednar\u010duk","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Dabi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Fo\u010da, University of East Sarajevo, 71123 Isto\u010dno Sarajevo, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"\u0160itum","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venerology, University Hospital Center \u201cSestre Milosrdnice\u201d, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Croatian Academy of Science and Arts, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snje\u017eana","family":"Popovi\u0107-Peji\u010di\u0107","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Department of Internal Medicine, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Academy of Science and Arts of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9431-0736","authenticated-orcid":false,"given":"Milo\u0161 P.","family":"Stojiljkovi\u0107","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-1781","authenticated-orcid":false,"given":"Ranko","family":"\u0160krbi\u0107","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Academy of Science and Arts of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina"},{"name":"Department of Pathologic Physiology, First Moscow State Medical University I.M. Sechenov, 119435 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Prtina, A., Ra\u0161eta Simovi\u0107, N., Milivojac, T., Vujni\u0107, M., Grabe\u017e, M., Djuric, D., Stojiljkovi\u0107, M.P., Soldat Stankovi\u0107, V., \u010coli\u0107, M.J., and \u0160krbi\u0107, R. (2021). The Effect of Three-Month Vitamin D Supplementation on the Levels of Homocysteine Metabolism Markers and Inflammatory Cytokines in Sera of Psoriatic Patients. Biomolecules, 11.","DOI":"10.3390\/biom11121865"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5114\/ada.2018.73136","article-title":"Level of inflammatory cytokines tumour necrosis factor \u03b1, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome","volume":"36","author":"Pirowska","year":"2019","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng2061","article-title":"Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn\u2019s disease susceptibility","volume":"39","author":"Parkes","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1096\/fj.04-1625fje","article-title":"Interleukin-6: A cytokine to forget","volume":"18","author":"Balschun","year":"2004","journal-title":"FASEB J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bu, J., Ding, R., Zhou, L., Chen, X., and Shen, E. (2022). Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880201"},{"key":"ref_8","first-page":"e2195","article-title":"Psoriasis and cardiovascular diseases: A literature review to determine the causal relationship","volume":"10","author":"Jindal","year":"2018","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1139\/cjpp-2018-0112","article-title":"Homocysteine and homocysteine-related compounds: An overview of the roles in the pathology of the cardiovascular and nervous systems","volume":"96","author":"Djuric","year":"2018","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case control study","volume":"157","author":"Gisondi","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Campanati, A., Marani, A., Martina, E., Diotallevi, F., Radi, G., and Offidani, A. (2021). Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111511"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yang, L., Zhang, L., Du, Q., Gong, X., and Tian, J. (2023). Exploring the molecular mechanism underlying the psoriasis and T2D by using microarray data analysis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-46795-5"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/15230860260220175","article-title":"Oxidative stress and its role in skin disease","volume":"4","author":"Trouba","year":"2002","journal-title":"Antioxid. Redox Signal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000289203","article-title":"TNF-alpha and obesity","volume":"11","author":"Tzanavari","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: Diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bajic, Z., Sobot, T., Amidzic, L., Vojinovic, N., Jovicic, S., Gajic Bojic, M., Djuric, D.M., Stojiljkovic, M.P., Bolevich, S., and Skrbic, R. (2024). Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome. Biomedicines, 12.","DOI":"10.3390\/biomedicines12061207"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1139\/cjpp-2022-0534","article-title":"Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats","volume":"101","author":"Zorislava","year":"2023","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"El-Shafey, M., El-Agawy, M.S.E., Eldosoky, M., Ebrahim, H.A., Elsherbini, D.M.A., El-Sherbiny, M., Asseri, S.M., and Elsherbiny, N.M. (2022). Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.862394"},{"key":"ref_21","first-page":"21-0007","article-title":"Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_22","first-page":"23-0017","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos","year":"2023","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","article-title":"Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: A systematic review and meta-analysis of prospective cohort and before-after studies","volume":"33","author":"Chang","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Vata, D., Tarcau, B.M., Popescu, I.A., Halip, I.A., Patrascu, A.I., Gheuca Solovastru, D.F., Mocanu, M., Chiriac, P.C., and Gheuca Solovastru, L. (2023). Update on Obesity in Psoriasis Patients. Life, 13.","DOI":"10.3390\/life13101947"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: A randomized clinical study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3945\/ajcn.115.125849","article-title":"Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomised trial: A prospective observational follow-up study","volume":"104","author":"Jensen","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2019.08.027","article-title":"Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in Psoriasis","volume":"133","author":"Packer","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101737","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: A prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/exd.12081","article-title":"Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques","volume":"22","author":"Faurschou","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis","volume":"169","author":"Arends","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/09546634.2019.1708853","article-title":"Liraglutide improved inflammation via mediating IL-23\/Th-17 pathway in obese diabetic mice with psoriasiform skin","volume":"32","author":"Chen","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","article-title":"Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin","volume":"19","author":"Soderstrom","year":"2017","journal-title":"AAPS J."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Liu, X.Q., Zhou, P.L., Yin, X.Y., Wang, A.X., Wang, D.H., Yang, Y., and Liu, Q. (2023). Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0293327"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","article-title":"Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis","volume":"304","author":"Yilmaz","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bai, B., and Chen, H. (2021). Metformin: A Novel Weapon Against Inflammation. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.622262"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lin, X., Meng, X., and Song, Z. (2019). Homocysteine and psoriasis. Biosci. Rep., 39.","DOI":"10.1042\/BSR20190867"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.5021\/ad.2019.31.4.378","article-title":"Association between Homocysteine Levels and Psoriasis: A Meta-Analysis","volume":"31","author":"Kim","year":"2019","journal-title":"Ann. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"541709","DOI":"10.1155\/2014\/541709","article-title":"Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis","volume":"2014","author":"Ataseven","year":"2014","journal-title":"Dis. Markers"},{"key":"ref_45","first-page":"102","article-title":"Changes of Serum Level of Homocysteine and Oxidative Stress Markers by Metformin and Inositol in Infertile Women with Polycystic Ovary Syndrome: A Double Blind Randomized Clinical Trial Study","volume":"16","author":"Janati","year":"2022","journal-title":"Int. J. Fertil. Steril."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:23:18Z","timestamp":1759850598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["biom15010046"],"URL":"https:\/\/doi.org\/10.3390\/biom15010046","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}